semaglutide alzheimer clinical trial Novo Nordisk Alzheimer's drug trials fail in blow to weight-loss giant New Alzheimer's Trial Reveals Surprising

Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system

The combination therapy of ERK kinase inhibitor trimetinib and DRP-104 significantly increased the survival rate of the homogeneous PDAC model (Encarnacin-Rosado et al., 2023)

Lee MMY, Ghouri N, McGuire DK, Rutter MK, Sattar N

Int J Mol Med (2014) 34(2):47582.10.3892/ijmm.2014.1787 39 Pacheco-PantojaELRanganathLRGallagherJAWilsonPJFraserWD

Jul 28 2010;58(14):8426-9

We titrate deliberately to minimize side effects, which means the first weeks often feel like the medication is barely doing anything on the craving front